SAB Biotherapeutics, Inc. (SABS) Stock Grade

About SAB Biotherapeutics, Inc.'s fundamentals

SAB Biotherapeutics is a small-cap biotechnology company with a market capitalization of $292.5 million that is currently unprofitable, with a net margin of 0.0% and no dividend yield. The company experienced a complete decline in year-over-year revenue, dropping 100%, indicating it is not generating commercial revenue at this time. Despite these challenges, the company's P/E ratio of 5.4 suggests relatively low valuation relative to earnings, and it maintains a return on equity of 8.8%, though this metric is less meaningful given the lack of profitability.